GGI
CRSP icon

Godsey & Gibb Inc’s CRISPR Therapeutics CRSP Stock Holding History

Godsey & Gibb Inc’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.89K Hold
108
– – ﹤0.01% 304
2026
Q1 		$5.14K Hold
108
– – ﹤0.01% 316
2025
Q4 		$5.66K Buy
+108
New +$6.47K ﹤0.01% 333
2024
Q2 		– Sell
-45
Closed -$3.07K – 409
2024
Q1 		$3.07K Buy
+45
New +$3.22K ﹤0.01% 334
2023
Q1 		– Sell
-200
Closed -$8.13K – 347
2022
Q4 		$8.13K Buy
+200
New +$10.6K ﹤0.01% 213
2022
Q3 		– Sell
-190
Closed -$12K – 106
2022
Q2 		$12K Buy
+190
New +$11.2K 0.01% 62

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Godsey & Gibb Inc's CRSP Position: Q2 2026 in Review

Godsey & Gibb Inc held its CRISPR Therapeutics (CRSP) position steady in Q2 2026 at 108 shares worth $5.89K. The position accounts for ﹤0.01% of the portfolio, ranked #304.

Godsey & Gibb Inc first reported a position in CRSP in Q2 2022 and has held it in 6 quarters since. The position peaked at $12K in Q2 2022. 524 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Godsey & Gibb Inc held 108 shares of CRISPR Therapeutics worth $5.89K as of Q2 2026.
  • Godsey & Gibb Inc left its CRISPR Therapeutics share count unchanged in Q2 2026.
  • CRISPR Therapeutics made up ﹤0.01% of Godsey & Gibb Inc's portfolio in Q2 2026, its #304 holding.
  • Godsey & Gibb Inc first reported a position in CRISPR Therapeutics in Q2 2022 and has held it in 6 quarters since.
  • Godsey & Gibb Inc's CRISPR Therapeutics position peaked at $12K in Q2 2022.
  • 524 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Godsey & Gibb Inc's 13F filing for Q2 2026, filed 13 Jul 2026.